Browsing by Author "Sezgin, Canfeza"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome
    (Lippincott Williams & Wilkins, 2007-01) Sezgin, Canfeza; Özdemir, Necmettin; Göker, Erdem; Kurt, Ender; Evrensel, Türkkan; Manavoğlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0002-9732-5340; AAJ-1027-2021; 7006207332; 6603942124; 6602587152
    Objective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes. Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 Mg/m(2)/d) in patients with anthra-cycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment. Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP. Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.
  • No Thumbnail Available
    Item
    Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma
    (Wiley, 2005-05) Sezgin, Canfeza; Veral, Ali; Karabulut, Bülent; Göker, Erdem; Kurt, Ender; Evrensel, Türkkan; Yalçınkaya, Ülviye; Kanat, Özkan; Demiray, Mutlu; Arslan, Murat; Ercan, İlker; Manavoǧlu, Osman; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; 0000-0002-2382-290X; 0000-0003-2501-3097; 0000-0002-9732-5340; M-8060-2019; AAJ-1027-2021; 7006207332; 6603942124; 6508300295; 55881548500; 6603631569; 57197925370; 6603789069; 6602587152
    In this study, we aimed to investigate the clinicopathological characteristics with special emphasis on c-kit expression and the treatment results of patients with extrapulmonary small cell carcinoma (EPSCC). The medical records of the patients with EPSCC were reviewed, and the data regarding patient and tumour characteristics, treatment and clinical outcome were retrieved and analysed. A total of 28 patients with the diagnosis of EPSCC were identified. There were 19 males and 9 females, with a mean age of 56.5 years. Patients with limited disease (LD) (n = 13) were treated with surgery, chemotherapy (CT) and radiotherapy with different sequences. Patients with extensive disease (ED) (n = 15) were mainly treated with combination CT. The median overall survival was 14.5 months in patients with LD compared to 11 months in those with ED (p = 0.029). Ten patients (36%) showed c-kit overexpression. There was no significant difference between the survival of c-kit-positive and c-kit-negative patients (p = 0.367). In conclusion, our study demonstrates that the prognosis of EPSCC is poor despite currently available treatments. C-kit may be considered as a potential target for novel therapeutical approaches.